Arana Therapeutics was a biotechnology company specialising in the development of next-generation antibody-based therapeutics to treat inflammation and cancer. It merged with Cephalon Inc. in 2009.
Arana developed a suite of high-affinity, humanised antibodies using its proprietary phage display technology platform. Its lead product, ART621, targeted TNF-alpha for the treatment of rheumatoid arthritis and other inflammatory diseases.
